key: cord-0014768-jok51uz4
authors: Mariamidze, E.; Mezquita, L.
title: ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update
date: 2021-01-04
journal: ESMO Open
DOI: 10.1016/j.esmoop.2020.100022
sha: e4438821e864a44313e4b75560254883a2387e71
doc_id: 14768
cord_uid: jok51uz4

nan

In this podcast, Dr Elene Mariamidze (a member of the ESMO Young Oncologists Committee and the Georgian Group of Young Oncologists) interviews Dr Laura Mezquita (Thoracic Oncology Group) regarding novelties presented in ESMO 2020 in the field of metastatic non-small-cell lung cancer (NSCLC).

Keynote-024 5-year overall survival (OS) update: first line Pembrolizumab versus platinum based chemotherapy in patients with metastatic NSCLC and programmed deathligand 1 (PD-L1) tumor proportion score 50%. This is one of the first trials to present 5-year OS in a metastatic subgroup of patients using IO. OS was 31.9% versus 16.3% in the Pembrolizumab and chemotherapy groups, respectively, with overall responce rate (ORR) at 3 years of 82% for Pembrolizumab. Patients were exposed to 2 years (35 cycles) of Pembrolizumab treatment in the experimental arm. The crossover rate from chemotherapy to Pembrolizumab upon progression was 66%. Long-term treatment with Pembrolizumab did not identify new safety signals. Incidence of any-grade and grade 3-5 treatment-related adverse events was lower in Pembrolizumab versus chemotherapy groups. The retreatment group that was re-exposed to Pembrolizumab for the second course (12 patients) had 33% ORRdthis opens a new niche for reinitiating IO in future trials and eventually maybe daily clinical practicedthough the data is not mature yet 1 .

In the era of the COVID-19 pandemic, exposure to a 6weekly instead of 3-weekly regimen of Pembrolizumab fixed dose is a sound option.

The fact that even in this selected population of PD-L1 50% tumor, a subset of patients still progressed on immunotherapy underlines the importance of identifying new biomarkers to help us choose the best options of therapy in the future.

None declared.

The authors have declared no conflicts of interest.

KEYNOTE-024 5-year OS update: First-line (1L) pembroliz umab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) 50%

FURTHER READING

OA 17.06 Updated analysis of KEYNOTE-024: pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 TPS 50%

Pembrolizumab versus chemotherapy for PD-L1epositive nonesmall-cell lung cancer

Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater

/© 2020 The Authors. Published by Elsevier Limited on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license